MDM2 is amplified in more than 40 different types of malignancies, including sarcomas, other solid tumours, and leukaemias (Casadei et al., 2019; Rayburn et al., 2005); therefore, with selection of appropriate probes, researchers may be able to identify DNA target sequences and specific DNA alterations in tumour tissue‐associated‐EVs, opening the possibility for more extensive study of EVs in relation to a wide array of diseases. This evidence concerns the gene MDM2 and neoplasm.